Publique un comentario 
Actualización del tratamiento de las hepatitis crónicas virales.
Resumen
crónicas por virus B, C y D, con referencia a trabajos publicados en la literatura especializada.
Palabras clave
Referencias
Malik AH, Lee WM. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 2000; 132:723-31.
Valdés García L. Enfermedades emergentes y reemergentes. La Habana: Ministerio de Salud Pública; 1998.
Delgado González G, Galindo Sardiña MA, Pérez Blanco P. Hepatitis B en Cuba: década de los 90 y más allá del 2000. En: Centro de Ingeniería Genética y Biotecnología. Aplicaciones médicas de la biotecnología. Biotecnología Habana' 99; 1999 Nov 28 - Dic 3 La Habana. La Habana: Elfos Scientiae; 1999.pp.O20-O21.
Alter MJ. Epidemiology of hepatitis C. J Gastroenterol Hepatol 1996; 8:319-23.
Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. J Gastroenterol Hepatol 1996; 8: 324-8.
Padrón GJ. Bases moleculares para el estudio de las hepatitis virales. La Habana: Elfos Scientiae; 1998.
Scully LJ. Treatment of chronic hepatitis B virus infection. Can J Gastroenterol 1997; 11:17- 20.
Di Bisceglie AM. Long-term outcome of interferon-alpha therapy for chronic hepatitis B. J Hepatol 1995; 22:65-7.
Perrillo RP. Interferon therapy of chronic hepatitis B. En: Arroyo V, Bosh J, Rodes J, Eds. Treatments in hepatology. Barcelona: Masson; 1995.pp.141-53.
Perrillo RP. Chronic hepatitis B: problem patients (including patients with decompensated disease). J Hepatol 1995; 22:45-8.
Grob PJ. Hepatitis B:virus, pathogenesis and treatment. Vaccine 1998; 16:11-6.
Minuk YG. Principles in the management of chronic hepatitis B viral infection. (review) Can J Gastroenterol 1999; 13:75-7.
Nicoll A, Locarnini S. Present and future directions in the treatment of chronic hepatitis B infection. (review) J Gastroenterol Hepatol 1997; 12: 843-54.
Morrey JD, Korba BE, Sidwell RW. Transgenic mice as a chemotherapeutic model for hepatitis B virus infection. Antivir Ther 1998; 3:59-68.
Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HWL, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;
:1256-63.
Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a
randomised trial. Gut 2000; 46:526-8.
Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-8.
Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HB e/ HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32:300-6.
Malkan G, Cattral MS, Humar A, AL Asghar H, Greig PD, Hemming AW, et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000; 69:1403-7.
Rey D, Fritsch S, Schmitt C, Partisani M, Kempf-Durepaire G, Nicolle M, et al. Emergence of resistan hepatitis B virus strains during long-term lamivudine therapy in human
inmunodeficiency virus co-infected patients. Gastroenterol Clin Biol 2000; 24:125-7.
Petry W, Erhardt A, Heintges T, Haussinger D. New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated? Z Gastroenterol 2000; 38:77-87.
Renner EL. Hepatitis B: when to use lamivudine? Schweiz Med Wochenschr 2000; 130:39- 41.
Huo T-I, Wu J-C, Lin R-Y, Sheng W-Y, Chang F-Y, Lee S-D. Decreasing hepatitis D virus infection in Taiwan: An analysis of contributory factors. J Gastroenterol Hepatol 1997;
:747-51.
Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, et al. Treatment of chronic hepatitis D with interferon alpha-2 a. N Engl J Med 1994; 330:88-94.
Van Leewen DJ, Dadrat A. Viral hepatitis and its imitators I: women's medicine. En: Blackwell RE, Ed. Cambridge: Blackwell Science; 1996.pp.324-38.
Carreño V, Bartolomé J, Madejón A. Hepatitis delta virus infection: molecular biology and treatment. Dig Dis 1994; 12:265-75.
González A, Esteban JI, Madoz P, Viladomiu L, Genesca J, Muñiz E, et al. Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: final report of a prospective trial. Hepatology 1995; 22:882-5.
National Institutes of Health. Chronic Hepatitis C: current disease management. New York: NIH; 2000 [Publication no 99-42 30].
National Institutes of Health. Consensus development conference: management of hepatitis C. Hepatology 1997; 26 (Suppl 1).
Spengler U, Rockstroh JK. Hepatitis C in the patient with human inmunodeficiency virus infection. J Hepatol 1998; 29: 1023-30.
Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995; 23:13-6.
Schvarcz R, Ando Y, Sonnenborg A, Weiland O. Combination treatment with interferon alfa- 2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained
response to interferon alone: swedish experience. J Hepatol 1995; 23:8-12.
Lam NP. Hepatitis C: natural history, diagnosis and management. Am J Health-Syst Pharm 1999; 56:961-76.
Mc Hutchison JG, Gordon SC, Schiff ER. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis. N Engl J Med 1998; 339:1485-92.
Lai MY. Firstline treatment for hepatitis C: combination interferon/ribavirin interferon monotherapy. J Gastroenterol Hepatol 2000; 15:130-3.
Olaso V, Córdoba J, Prieto M. Tratamiento de la hepatitis crónica C. Rev Esp Enf Dig 1997; 89:621-37.
Moscarella S, Buzzelli G, Romanelli RG, Monti M, Giannini C, Careccia G, et al. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary
results. Liver 1998; 18:366-9.
Levine RA. Treating histologically mild chronic hepatitis C: monotherapy, combination therapy, or tincture of time? Ann Intern Med 1998; 129:323-6.
Van Thiel DH, Friedlander L, Mallory P, Fagivoli S, Wright HI, Gasbarrin A, et al. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and
withaut phlebotomy. Gastroenterology 1994; 106:1002.
Arús Soler E. Estado actual del tratamiento de las hepatitis virales crónicas. Jornadas LUSO-Cubanas de Gastrenterologia em Medicina Geral e Familiar; 2000 Jul 21-26; Varadero. Lisboa: Faculdade de Ciencias Médicas de Lisboa; 2000.pp.36-39.
Kobayashi M, Chayama K, Arase Y, Tsubota A, Saitoh S, Susuki Y, et al. Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with
interferon a. J Gastroenterol 1999; 34:94-9.
Gish GR. Future directions in the treatment of patients with chronic hepatitis C virus infection. Can J Gastroenterol 1999; 13:57-62.
Enlaces refback
- No hay ningún enlace refback.
Copyright (c) 2020 Norlan de la Cruz Alfonso, Rolando Martínez López
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.
La revista está: Certificada por el CITMA
La revista es de acceso abierto y gratuito.